An estimated 10 million people worldwide live with Parkinson’s disease, yet most receive diagnoses only after substantial brain damage has already occurred. This diagnostic lag exists because current clinical approaches rely on observable symptoms and dopamine transporter imaging, both of which reflect advanced neurodegeneration.
A new breakthrough changes this trajectory. Researchers have developed [11C]MODAG-005, a PET tracer capable of detecting alpha-synuclein protein clumps years before symptoms typically manifest. The tracer demonstrates exceptional sensitivity, with 2.8 times higher binding in key brain regions of affected patients compared to healthy controls.
This advance means that future patients with synucleinopathies could receive diagnosis at the preclinical stage, when neuroprotective interventions may offer the greatest benefit. Early detection through molecular imaging represents a paradigm shift in Parkinson’s disease management.
Read the full article on GMJ Newsroom.
Was this article helpful?
